Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by QualityTeston Dec 05, 2020 10:50am
248 Views
Post# 32043736

RE:RE:Faith Shaken

RE:RE:Faith ShakenJ4P & Priceless, 

"I would say settling on a poor low ball  deal would be a very bad decision from management IMO, they would be best to take the PP and wait it out for a best deal they can get. "

I don't think this is an issue of RVX being impatient and accepting a rushed deal. BTD what, 10 months ago? They've had a lot of time to get a deal with BP finalized, if BP is interested. 

"
I am assuming this company has way too much potential to be off the BP radar."

I lean in that direction as well given the market value of SGLT2s and their expected growth over the next few years (combined w/ patent extensions), but I am a little concerned that the market has so fully discounted us. Combine that with kidney + glucose info and this has blockbuster potential.

Tax loss selling may be partly to blame for this week I suppose.

Doubters and shorters have been correct when it comes to this stock for a while now, so it wouldn't be a shock if they continue to be correct. At least by Jan 15th we should whether the PP went through or not, and that will be a good indication of whether we've been sold down the river or not, imo. 

Trying to focus on BTD in major cardio indication, ORI extension + conversion of debenture, and the latest potential PP which RVX can back out of it if it's not needed. Together, these paint a decent picture but it seems like we are using invisible ink on our picture.

What was that Buffet said about being greedy when others are fearful...
<< Previous
Bullboard Posts
Next >>